✅ Model Answer: • Condition: Erythema infectiosum (Fifth disease) caused by Parvovirus B19.
• Rash pattern: Bright red, confluent 'slapped cheek' appearance on both cheeks, followed by a lacy, reticular (net-like) rash on the trunk and extremities. The rash may wax and wane and is exacerbated by heat, sunlight, or exercise.

✅ Model Answer: • Etiologic agent: Parvovirus B19 (single-stranded DNA virus).
• Target cell: Erythroid progenitor cells in the bone marrow (due to the virus's tropism for P antigen on erythroblasts).
• This leads to transient suppression of erythropoiesis.

✅ Model Answer: • Transmission: Respiratory droplets (coughing, sneezing), also through blood products and vertical transmission (mother to fetus).
• Contagious period: During the prodromal phase (before the rash appears). Patients are NOT contagious once the rash develops.
• Incubation period: 4-21 days.

✅ Model Answer: • Prodromal symptoms (7-10 days before rash):
- Mild fever (low-grade).
- Headache.
- Malaise and fatigue.
- Coryza (runny nose).
- Sore throat.
- Myalgia.
• These symptoms are often mild and may go unnoticed.

✅ Model Answer: • Stage 1 (Days 1-3): 'Slapped cheek' rash – bright red, confluent erythema on both cheeks, sparing the nasolabial folds and perioral area.
• Stage 2 (Days 2-7): Lacy, reticular (net-like) rash on the trunk, arms, and legs. May be more prominent on extensor surfaces.
• Stage 3 (Weeks): Rash may wax and wane for 1-3 weeks. Exacerbated by heat, sunlight, exercise, or stress.

✅ Model Answer: • Transient aplastic crisis: Parvovirus B19 infects erythroid progenitor cells, causing temporary cessation of red blood cell production.
• In patients with chronic hemolytic anemias (sickle cell disease, thalassemia, hereditary spherocytosis), this can lead to severe anemia with a sudden drop in hemoglobin.
• Presentation: Pallor, fatigue, tachycardia, shortness of breath, reticulocytopenia (reticulocyte count near zero).
• Management: May require blood transfusion (PRBCs). The crisis resolves when the immune system clears the virus.

✅ Model Answer: • Risk: Parvovirus B19 can cross the placenta and infect the fetal erythroid progenitor cells.
• Complications: Fetal anemia, hydrops fetalis (fetal edema, ascites, pleural effusions), and fetal loss.
• Risk by trimester:
- First trimester: Risk of fetal loss ~10-15%.
- Second trimester: Risk of hydrops ~5-10%.
- Third trimester: Risk is low.
• Management: Serial ultrasound monitoring (fetal Doppler) and intrauterine transfusion if severe fetal anemia is detected.

✅ Model Answer: • Supportive care: No specific antiviral treatment is available.
- Analgesics/antipyretics: Paracetamol or ibuprofen for fever and discomfort.
- Hydration: Ensure adequate fluid intake.
- Rest.
- Avoid triggers: Avoid heat, sunlight, and strenuous activity that may worsen the rash.
• No isolation needed once the rash appears (patient is no longer contagious).

✅ Model Answer: • Chronic anemia (persistent infection): Immunocompromised patients (HIV, transplant recipients, chemotherapy patients) may not clear the virus, leading to persistent parvovirus B19 infection and chronic anemia.
• Presentation: Persistent reticulocytopenia, severe anemia requiring repeated transfusions.
• Diagnosis: Parvovirus B19 DNA by PCR (detects persistent infection).
• Treatment: IV immunoglobulin (IVIG) can help clear the virus and resolve anemia.
• Prognosis: Good with IVIG therapy.

✅ Model Answer: • Arthropathy: Occurs in ~20% of children and up to 60% of adults (especially women).
• Presentation: Symmetrical polyarthropathy affecting hands, wrists, knees, and ankles; joint pain, stiffness, swelling.
• Duration: Usually self-limited, resolves within weeks to months.
• Management: Symptomatic treatment with NSAIDs (ibuprofen, naproxen).
• Note: Chronic arthritis is rare but can occur; not associated with joint destruction like rheumatoid arthritis.

✅ Model Answer: • Clinical diagnosis: Classic 'slapped cheek' and lacy reticular rash in a well-appearing child is highly suggestive.
• Laboratory:
- Serology: Parvovirus B19 IgM (acute infection) – positive in first 2-3 months; IgG (past infection).
- PCR: Detection of parvovirus B19 DNA from blood, respiratory secretions, or tissue.
- Reticulocyte count: Low or zero in aplastic crisis.
- Complete blood count: For anemia evaluation in high-risk patients.

✅ Model Answer: • Measles (rubeola): Koplik spots, more severe prodrome, rash starts on face then spreads downward, fever.
• Scarlet fever: Sandpaper-like rash, strawberry tongue, sore throat, fever, Group A strep.
• Roseola (HHV-6): High fever followed by rash (maculopapular) after fever resolves.
• Rubella (German measles): Pink maculopapular rash, postauricular lymphadenopathy, usually milder.
• Drug eruption: History of medication use.
• Erythema multiforme: Target lesions, often triggered by HSV or drugs.

✅ Model Answer: • "Your child has Fifth disease (erythema infectiosum), a mild viral illness caused by parvovirus B19."
• "The rash is the hallmark of the disease – it starts on the cheeks ('slapped cheek') and then spreads to the body with a lacy pattern."
• "Your child is no longer contagious now that the rash has appeared. They can return to school/daycare."
• "The rash may come and go for a few weeks, especially with heat or exercise – this is normal and no cause for concern."
• "Give paracetamol or ibuprofen for fever or discomfort. Make sure your child drinks plenty of fluids."
• "If your child has a chronic anemia condition (like sickle cell), let us know immediately, as they may need monitoring."

✅ Model Answer: • P antigen (globoside): A blood group antigen found on erythroid progenitor cells, erythrocytes, and other tissues.
• Role: Parvovirus B19 uses the P antigen as a cellular receptor to enter and infect cells.
• Significance:
- Individuals who are P antigen-negative (rare, about 0.1% of the population) are resistant to parvovirus B19 infection.
- Erythroid progenitor cells are the primary target, leading to the characteristic erythroid suppression.

✅ Model Answer: • IVIG (intravenous immunoglobulin): Contains neutralizing antibodies against parvovirus B19.
• Indications:
- Chronic parvovirus B19 infection in immunocompromised patients (HIV, transplant recipients).
- Chronic anemia with reticulocytopenia and parvovirus DNA persistence.
- Severe fetal anemia/hydrops fetalis (through intrauterine transfusion).
• Dose: 400 mg/kg/day for 5 days, or 1 g/kg/day for 2 days.
• Response: Usually effective in clearing the virus and resolving anemia within weeks.